Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3804379 in Healthy Participants and MASH Patients
NCT06575400Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3804379 in metabolic dysfunction-associated steatohepatitis (MASH) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-Emergent Adverse Events at Day 235. Started Sep 2024; status: recruiting.
02
Drugs
BI 3804379
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06575400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575400.